<DOC>
	<DOCNO>NCT02350530</DOCNO>
	<brief_summary>BACKGROUND : For patient liver-limited metastatic colorectal cancer ( mCRC ) , complete resection liver metastases potentially curative treatment . The current goal medical treatment colorectal cancer initially unresectable liver metastasis maximize rate secondary resection prolong overall survival ( OS ) . A strong correlation find response rate secondary resection rate metastasis , triple drug combination infusional 5-fluorouracil/leucovorin ( 5-FU/LV ) , irinotecan , oxaliplatin ( FOLFOXIRI ) recommend use select patient potentially resectable metastasis order improve response rate make resection possible . The addition anti-VEGFs monoclonal antibody bevacizumab chemotherapy show increase response rate , resection rate improve OS first-line treatment mCRC patient . The efficacy safety bevacizumab addition triplet drug previously test OLIVIA trial , resection rate liver metastases 49 % report , response rate 81 % ; common grade 3-4 adverse event neutropenia . On basis promising result , conduct present randomize study explore whether FOLFOXIRI plus bevacizumab compare FOLFOXIRI alone first-line treatment could improve radical resectability patient RAS mutation-type , unresectable liver-only metastatic colorectal cancer . OBJECTIVE : The primary objective FOBULM study evaluate efficacy FOLFOXIRI plus bevacizumab compare FOLFOXIRI alone patient initially unresectable liver-limited RAS mutation-type mCRC . Secondary objective safety tolerability treatment , efficacy term objective response rate ( ORR ) , OS , progression free survival ( PFS ) , quality life assessment biomarkers predictive response prognosis .</brief_summary>
	<brief_title>FOLFOXIRI With Without Bevacizumab First-line Treatment Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type</brief_title>
	<detailed_description>OVERVIEW OF TRIAL DESIGN This FOCULM trial two-arm , multicenter , open label , prospective , randomized phase II study . Eligible patient initially unresectable liver-limited mCRC randomise 1:1 receive either FOLFOXIRI plus bevacizumab FOLFOXIRI alone .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Willing able provide write informed consent 2 . Histological cytological documentation adenocarcinoma colon rectum . 3 . Male female subject &gt; 18 year &lt; 70 age . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 5 . There must documentation CT scan , MRI , intraoperative palpation patient evidence metastasis confine liver . 6 . The liver metastases must assess multidisciplinary team include hepatic surgeon approve participate study unresectable base least one four criterion : 1 . All liver metastasis complete resect negative margin ; 2 . No ability preservation two contiguous hepatic segment ; 3 . No ability preservation adequate vascular inflow outflow well biliary drainage ; 4 . Complete resection would require great 70 % liver parenchyma remove . 7 . The colorectal primary tumor metastatic tumor must determine KRAS ( exon 2 codon 12 13 ; exon 3 codon 59 61 ; exon 4 codon 117 146 ) NRAS ( exon 2 codon 12 13 ; exon 3 codon 59 61 ; exon 4 codon 117 146 ) mutationtype . 8 . Primary tumor regional node resect clear surgical margin ; unresected primary tumor plan radical resect primary tumor . 9 . No previous systemic anticancer therapy metastatic disease ( adjuvant chemotherapy nonmetastatic disease allow terminate 6 month ago ) . 10 . Adequate bone marrow , hepatic renal function assess follow laboratory requirement conduct within 7 day start study treatment : Hemoglobin ( Hb ) ≥ 90g/ L , absolute neutrophil count ( ANC ) ≥ 1.5×109/ L , platelet count ≥ 100×109/ L ; Total bilirubin ≤ 1.5×the upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 5 ×ULN ; Serum creatinine ≤1.5×the ULN . 1 . Any evidence extrahepatic metastasis , lymph node ( include portal lymph node ) metastasis primary tumor recurrence . 2 . Previous hepatic resection and/or ablation , hepatic arterial infusion therapy , radiation therapy liver . 3 . Previous concurrent cancer distinct primary site histology colorectal cancer within 5 year prior randomization . 4 . Significant cardiovascular disease include unstable angina myocardial infarction within 6 month initiate study treatment . 5 . Heart failure grade III/IV ( NYHAclassification ) . 6 . Unresolved toxicity high CTCAE v.4.0 Grade 1 attribute prior therapy/procedure . 7 . Subjects know allergy study drug excipients . 8 . Current recent ( within 4 week prior start study treatment ) treatment another investigational drug participation another investigational study . 9 . Breast feed pregnant woman 10 . Lack effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Liver metastasis</keyword>
	<keyword>Liver resection</keyword>
	<keyword>Liver ablation</keyword>
	<keyword>Conversion therapy</keyword>
	<keyword>FOLFOXIRI</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>RAS mutation</keyword>
</DOC>